JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 38 No. 11 1711-1717
© 1997 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pirker, W.
Right arrow Articles by Brücke, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pirker, W.
Right arrow Articles by Brücke, T.

Iodine-123-Epidepride-SPECT: Studies in Parkinson's Disease, Multiple System Atrophy and Huntington's Disease

Walter Pirker, Susanne Asenbaum, Sylvia Wenger, Johannes Kornhuber, Peter Angelberger, Lüder Deecke, Ivo Podreka and Thomas Brücke

University Clinics for Neurology and Nuclear Medicine, Vienna, Austria; Department of Psychiatry, University of Göttingen, Göttingen, Germany; Forschungszentrum Seibersdorf, Seibersdorf, Austria

Correspondence: For correspondence or reprints contact: Walter Pirker, MD, Neurological University Clinic, Währinger Gürtel 18–20, A-1090 Vienna, Austria.

ABSTRACT

Epidepride is a benzamide derivative with very high affintty for D2 receptors, which, in its [123]-labeled form, can be used for SPECT. The aim of this study was to evaluate the usefulness and accuracy of [123]epidepride-SPECT for the differential diagnosis of movement disorders. Methods: SPECT imaging with a triple-headed scintillation camera was performed in 9 patients with Parkinson's disease, 9 patients with probable multiple system atrophy (MSA), 1 patient with progressive supranuclear palsy, 16 patients with Huntington's disease (HD) and 14 controls, 3 hr after the intravenous injection of 3.7 ± 1.3 mCi of [123]epidepride. The striatum-to-cerebellum ratio - 1, reflecting the speciflc-to-nondisplaceable binding ratio, was used as a semiquantitative measure of D2 receptor binding. Results: Kinetic studies showed peak striatal uptake about 3 hr post injeclion and a slow decline thereafter. The striatum-to-cerebellum ratio-1 was significantly reduced in MSA(11.8 ± 3.9, compared to controls, 19.0 ± 6.3; p < 0.01) and in patients with HD (8.8 ± 3.2; p < 0.00005) but normal in Parkinson's disease (15.8 ± 3.6; not significant). A high interindividual variation of specific striatal epidepride binding (striatum - cerebellum; cpm/mCi x kg) was found in controls and in all patient groups. The interindividual variation of striatum-to-cerebellum ratios was lower but still considerable. In half of the MSA patients, the specific-to-nondisplaceable binding ratio fell with in the range of controls. The use of various cortical reference regions did not improve discrimination between MSA and controls or Parkinson's disease patients, respectively. The discrimination of HD patients from controls was better, with overlap in only two cases. In one HD patient, calculation of the striatum-to-cerebellum ratio was almost impossible due to extremely low nonspecific binding. Possible explanations for the large variation of the ratios, resulting in an overlap between controls and different patient groups, are very low counting rates in the reference region and the fact that a transient binding equilibrim may not be achieved after bolus injection of epidepride. Conclusion: Epidepride appears to be a useful SPECT ligand for studying dopamine D2 receptors. However, its markedly higher specific-to-nondisplaceable binding ration in comparision to those of iodobenzamide or other D2 ligands did not result in a better discrimination between different basal ganglia disorders. The calculation of plasma input curves and volumes of distribution might improve the accuracy of [123]epidepride-SPECT.

Key Words: dopamine • D2 receptors • epidepride • SPECT • basal ganglia disorders




This article has been cited by other articles:


Home page
RadiologyHome page
D. A. Hammoud, J. M. Hoffman, and M. G. Pomper
Molecular Neuroimaging: From Conventional to Emerging Techniques
Radiology, October 1, 2007; 245(1): 21 - 42.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
E. E. Camargo
Brain SPECT in Neurology and Psychiatry
J. Nucl. Med., April 1, 2001; 42(4): 611 - 623.
[Abstract] [Full Text]


Home page
Br. J. PsychiatryHome page
C. M. E. STEPHENSON, V. BIGLIANI, H. M. JONES, R. S. MULLIGAN, P. D. ACTON, D. VISVIKIS, P. J. ELL, R. W. KERWIN, and L. S. PILOWSKY
Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo: [123I]-epidepride single photon emission tomography(SPET) study
The British Journal of Psychiatry, November 1, 2000; 177(5): 408 - 415.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1997 by the Society of Nuclear Medicine.